Structure

InChI Key YTNKWDJILNVLGX-UHFFFAOYSA-N
Smile COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC.Cl
InChI
InChI=1S/C19H27N5O4.ClH/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19;/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23);1H

Physicochemical Descriptors

Property Name Value
Molecular Formula C19H28ClN5O4
Molecular Weight 425.92
AlogP 1.35
Hydrogen Bond Acceptor 8.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 8.0
Polar Surface Area 111.83
Molecular species NEUTRAL
Aromatic Rings 2.0
Heavy Atoms 28.0

Pharmacology

Action Mechanism of Action Reference
AGONIST Adrenergic receptor alpha-1 agonist DailyMed

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Prostatic Hyperplasia 4 D011470 ClinicalTrials
Kidney Calculi 3 D007669 ClinicalTrials
Ureterolithiasis 3 D053039 ClinicalTrials

Related Entries

Parent

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
Nervous system disorders
15.54
General disorders and administration site conditions
10.47
Cardiac disorders
9.94
Vascular disorders
9.05
Skin and subcutaneous tissue disorders
6.75
Injury, poisoning and procedural complications
5.86
Gastrointestinal disorders
5.39
Psychiatric disorders
4.71
Respiratory, thoracic and mediastinal disorders
4.55
Renal and urinary disorders
4.5
Investigations
3.56
Musculoskeletal and connective tissue disorders
3.09
Blood and lymphatic system disorders
2.83
Reproductive system and breast disorders
2.2
Metabolism and nutrition disorders
2.04

Cross References

Resources Reference
ChEBI 32286
ChEMBL CHEMBL1723
EPA CompTox DTXSID3045514
FDA SRS 75046A1XTN
Guide to Pharmacology 7109
KEGG D07124
PubChem 71764
SureChEMBL SCHEMBL179910
ZINC ZINC01843099